West Lafayette, IN, United States of America

D James Morrè

This inventor holds 1 USPTO granted patent. Top assignee: Mor-Nuco Enterprises, Inc.. Active years: 2016.


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: D James Morrè: Innovator in Cancer Detection

Introduction

D James Morrè is a notable inventor based in West Lafayette, Indiana, recognized for his contributions to cancer detection and diagnosis. With a focus on innovative methods and compositions, he has made significant strides in the field of medical diagnostics.

Latest Patents

Morrè holds a patent for "Methods and compositions for single chain variable region ENOX2 antibodies for cancer detection and diagnosis." This patent addresses the detection of various ENOX2 cancer isoforms shed into circulation by tumors of different cellular or tissue origins. The methods disclosed in this patent allow for the identification of the cell type and tissue of origin of neoplasms based on the patterns and molecular weights of these isoforms. Furthermore, the relative amounts of ENOX2 are proportional to tumor burden, providing a reliable measure of therapy response and disease progression. The patent also includes the amino acid sequence to which the scFv antibodies bind, establishing the molecular basis for the specificity of the test.

Career Highlights

Morrè's career is marked by his dedication to advancing cancer diagnostics. His work has not only contributed to the scientific community but has also paved the way for improved patient outcomes through early detection and targeted therapies.

Collaborations

Morrè collaborates with talented individuals such as Brandon Eugene Hostetler and James Jinpal Kim, enhancing the innovative efforts at Mor-nuco Enterprises, Inc.

Conclusion

D James Morrè's innovative work in cancer detection exemplifies the impact of scientific research on healthcare. His contributions continue to influence the field and improve diagnostic methods for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…